Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Ocular Therapeutix is a biopharmaceutical company specializing in innovative ophthalmic treatments. It develops bioresorbable hydrogel-based drug delivery systems for retinal diseases, glaucoma, and ocular inflammation. Its core products include DEXTENZA, an FDA-approved corticosteroid, and pipeline candidates like AXPAXLI for wet AMD and PAXTRAVA for glaucoma. The company's technology aims to reduce treatment burden, improve patient compliance, and address unmet needs in eye care markets.
This description was generated via AI from an annual report. Updated about 1 year ago.